Analyst Price Targets — CLDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 10, 2026 12:08 pm | — | UBS | $45.00 | $30.21 | TheFly | Celldex price target raised to $45 from $38 at UBS |
| May 13, 2026 10:48 am | Derek Archila | Wells Fargo | $54.00 | $32.00 | TheFly | Celldex price target raised to $54 from $38 at Wells Fargo |
| May 8, 2026 10:10 am | — | Barclays | $48.00 | $33.32 | TheFly | Celldex price target raised to $48 from $45 at Barclays |
| April 20, 2026 9:20 am | — | Barclays | $45.00 | $34.55 | TheFly | Celldex upgraded to Overweight from Underweight at Barclays |
| December 17, 2025 10:58 am | — | Barclays | $24.00 | $26.68 | TheFly | Celldex price target raised to $24 from $21 at Barclays |
| November 11, 2025 10:24 am | — | Barclays | $21.00 | $22.67 | TheFly | Celldex price target lowered to $21 from $25 at Barclays |
| October 13, 2025 9:27 am | — | Barclays | $25.00 | $26.77 | TheFly | Celldex initiated with an Underweight at Barclays |
| March 20, 2025 7:51 am | — | Morgan Stanley | $46.00 | $19.88 | TheFly | Celldex initiated with an Overweight at Morgan Stanley |
| October 29, 2024 7:25 am | Joseph Pantginis | H.C. Wainwright | $80.00 | $27.12 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX) |
| September 25, 2024 3:10 pm | Derek Archila | Wells Fargo | $44.00 | $36.02 | TheFly | Celldex upgraded to Overweight from Equal Weight at Wells Fargo |
Latest News for CLDX
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company's Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and…
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in…
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum…
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul,…
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N. J. , June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLDX.
U.S. House Trading
No House trades found for CLDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.